Neoplasms, Plasma Cell: all 2,314 studies

Page 5 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.

• Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)TerminatedNCT02576977Phase 3Results posted
• A Phase 1 Study in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT02561962Phase 1Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTerminatedNCT02548962Phase 1/2Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaCompletedNCT02541383Phase 3Results posted
• BiRd vs. Rd as Initial Therapy in Multiple MyelomaTerminatedNCT02516696Phase 3Results posted
• Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma PatientsCompletedNCT02514239Phase 1Results posted
• Leflunomide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02509052Phase 1/2Results posted
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 2Results posted
• UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib TreatmentCompletedNCT02499081Phase 2Results posted
• Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple MyelomaCompletedNCT02492750Phase 1Results posted
• Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaCompletedNCT02481934Phase 1Results posted
• Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02477215Phase 1/2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)CompletedNCT02440464Phase 2Results posted
• Optimising Renal Outcome in Myeloma Renal FailureCompletedNCT02424851Phase 2Results posted
• High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple MyelomaCompletedNCT02416206Phase 2Results posted
• Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple MyelomaCompletedNCT02412878Phase 3Results posted
• Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic CancerTerminatedNCT02376933Not applicableResults posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaTerminatedNCT02353572Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT02353468Phase 2Results posted
• Selinexor Treatment of Refractory MyelomaCompletedNCT02336815Phase 2Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple MyelomaCompletedNCT02331368Phase 2Results posted
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Phase 3Results posted
• Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT02290431Phase 2Results posted
• 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT02289222Phase 1/2Results posted
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedNCT02279394Phase 2Results posted
• Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in JapanCompletedNCT02272803Phase 2Results posted
• Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaTerminatedNCT02254551Phase 2Results posted
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02224729Phase 2Results posted
• Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaCompletedNCT02215967Phase 1Results posted
• An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1Results posted
• UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles VirusCompletedNCT02192775Phase 2Results posted
• Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple MyelomaCompletedNCT02186834Phase 1/2Results posted
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell TransplantCompletedNCT02181413Phase 3Results posted
• Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple MyelomaCompletedNCT02168101Phase 2Results posted
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCompletedNCT02159365Phase 2Results posted
• Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal DiseaseCompletedNCT02158052Not applicableResults posted
• Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple MyelomaCompletedNCT02148913Phase 1Results posted
• UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionTerminatedNCT02128230Phase 2Results posted
• Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT02119468Phase 1/2Results posted
• A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous TransplantationTerminatedNCT02112045Phase 2Results posted
• PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsCompletedNCT02104427Phase 2Results posted
• Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedNCT02100657Phase 1Results posted
• QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02099539Phase 1Results posted
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedNCT02098109Phase 2Results posted
• Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02086552Phase 2Results posted
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
• A Study of Avastin (Bevacizumab) in Patients With Multiple MyelomaTerminatedNCT02079519Phase 2Results posted
• A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's LymphomaCompletedNCT02078102Phase 2Results posted
• A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT02076009Phase 3Results posted
• Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT02075021Phase 1/2Results posted
• Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916CompletedNCT02064387Phase 1Results posted
• MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple MyelomaCompletedNCT02057640Phase 1/2Results posted
• Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple MyelomaCompletedNCT02046070Phase 2Results posted
• Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple MyelomaTerminatedNCT02043860Phase 1Results posted
• Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell DyscrasiasCompletedNCT02041325Phase 2Results posted
• Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
• A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)TerminatedNCT02036502Phase 1Results posted
• Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line TherapyTerminatedNCT02020941Phase 2Results posted
• Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02011113Phase 2Results posted
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaActive, not recruitingNCT02004275Phase 1/2Results posted
• Carfilzomib With Bendamustine and Dexamethasone in Multiple MyelomaTerminatedNCT02002598Phase 1/2Results posted
• A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaTerminatedNCT01999335Phase 1Results posted
• ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaTerminatedNCT01997840Phase 1/2Results posted
• CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationCompletedNCT01995708Phase 1Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01989598Phase 2Results posted
• An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiDCompletedNCT01985126Phase 2Results posted
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01980589Phase 1Results posted
• Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref MyelomaTerminatedNCT01979276Phase 1/2Results posted
• Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple MyelomaTerminatedNCT01969565Phase 2Results posted
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple MyelomaTerminatedNCT01965834Phase 2Results posted
• Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2Results posted
• SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01955434Phase 2Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal DiseaseCompletedNCT01949532Phase 1Results posted
• Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01946152Phase 1/2Results posted
• Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)TerminatedNCT01927718Not applicableResults posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory MyelomaCompletedNCT01903811Phase 2Results posted
• Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01899326Not applicableResults posted
• Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma PatientsTerminatedNCT01897714Phase 1/2Results posted
• CT Antigen TCR-Engineered T Cells for MyelomaTerminatedNCT01892293Phase 1/2Results posted
• PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TerminatedNCT01891643Phase 3Results posted
• Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT01889420Phase 1Results posted
• UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple MyelomaCompletedNCT01884688Phase 2Results posted
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaTerminatedNCT01881789Phase 1/2Results posted
• Cabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaCompletedNCT01866293Phase 1/2Results posted
• Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk MyelomaCompletedNCT01858558Phase 2Results posted
• A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple MyelomaCompletedNCT01852799Phase 2Results posted
• Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous TransplantCompletedNCT01852591Not applicableResults posted
• IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01850524Phase 3Results posted
• Study of SyB L-0501 to Treat Relapsed/Refractory Multiple MyelomaCompletedNCT01849848Phase 2Results posted
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaCompletedNCT01849783Phase 2Results posted
• Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01842308Phase 1/2Results posted
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT01832727Phase 1/2Results posted
• Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal ImpairmentCompletedNCT01830816Phase 1Results posted
• WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationCompletedNCT01827137Phase 1/2Results posted
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Phase 3Results posted

← Neoplasms, Plasma Cell overview